U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06826768) titled 'A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC' on Feb. 10.
Brief Summary: A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab
Study Start Date: May 01, 2025
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Intervention:
DRUG: REGN5678
Given by IV infusion
DRUG: Cemiplimab
Given by IV infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services with permission from Health Daily Digest....